AbbVie Makes $63B Bid for Botox Maker Allergan - NBC Connecticut
National & International News
The day’s top national and international news

AbbVie Makes $63B Bid for Botox Maker Allergan

Regulators and Allergan shareholders still need to approve the deal



    5 Ways Technology Can Make Your Life Easier
    This March 20, 2002 file photo shows a vial of Botox, made by Allergan. (AP Photo/Damian Dovarganes)

    AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at about $63 billion.

    The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45% premium to Allergan's closing price Monday.

    Shares of Allergan Plc, based in Dublin, Ireland, jumped nearly 30% before the opening bell.

    AbbVie shareholders will own 83% of the specialty drug company combination after the deal's completion while Allergan shareholders will have a 17% stake.

    Footage Shows Mom's Pleas as Baby is Rescued From Hot Car

    [NATL] Footage Shows Mom's Emotional Pleas After Baby Rescued From Hot Car

    Police released footage of a mother who said she accidentally left her 5-month-old in a car for half an hour in a Goodyear, Arizona, parking lot when she, her sister and other daughter went into the store. Officers are heard on camera saying it was about 99 degrees outside. 

    (Published Thursday, Aug. 22, 2019)

    Regulators and Allergan shareholders still have to approve the deal.

    Shares of AbbVie Inc., based in North Chicago, Illinois, sank 10%.